Mary Caffrey

Results from the second major renal outcomes trial for an SGLT2 inhibitor affirm the role of the class in preventing renal decline and kidney failure.

The PARALLAX study points to potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction, which has no approved treatments.

Results from the phase 3 EXPLORER-HCM trial show mavacamten may finally offer a therapeutic solution for patients with hypertrophic cardiomyopathy.

A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients.

A new analysis from the REDUCE-IT trial finds that cardiovascular benefits of Vascepa are consistent no matter what type of statin a patient takes for cholesterol.

A study finds that too few of patients classified as very high risk under European criteria are meeting 2019 LDL cholesterol targets because they don't get enough medication.

A Dutch study shows how genetic testing can help couples avoid passing devastating kidney diseases to their children, but it raises issues of disparities.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, associate editor of Evidence-Based Oncology, and vice president of the Community Oncology Alliance, discusses his new book.

German researchers find viral RNA in kidneys of patients who died from COVID-19.

An HHS report outlines efforts to reduce kidney failure and increase options such as home-based dialysis. COVID-19 has made kidney care a higher priority.

An agreement will tap Caris Life Sciences' next-generation sequencing technology to identify patients for Merus’ phase 1/2 eNRGy trial.

Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.

As the American Society of Clinical Oncology calls for more aggressive efforts to bring equity to cancer care, authors in JAMA Oncology say COVID-19 is creating wider gaps.

A study in Annals of Internal Medicine shows severe obesity presents a greater risk of death from COVID-19 than related factors such as diabetes or hypertension.

The American College of Cardiology updates guidance on prescribing SGLT2 inhibitors and GLP-1 receptor agonists to patients with type 2 diabetes and cardiovascular disease or CV risk.

The ruling reversed a lower court ruling regarding the drug discount program for hospitals that serve patients covered by Medicaid.

A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.

The ADAURA trial was stopped in April 2020 after an independent monitoring committee called for the trial to be unblinded 2 years early based on a determination of overwhelming efficacy.

Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.

Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from polycystic kidney disease (PKD) can grow to be about the size of a football weigh up to 30 pounds

Through the partnership, Humana and Heal will expand the startup’s current markets to include Chicago, Charlotte, Houston and others that are part of Bold Goal, a multi-year effort to improve overall health of communities by addressing both medical needs and working with partners to address social determinants of health, such as food insecurity.

FDA increased oversight of antibody testing on May 5, requiring them to meet standards of other molecular tests.

Data from DAPA-CKD show that the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes. The announcement comes after a data monitoring committee halted the trial in March 2020 when it found the evidence of efficacy was overwhelming.

Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning

Just when renal replacement therapy should start after acute kidney injury has been debated.

The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.

Writing in Nature, scientists found the antibodies fell into 2 distinct groups, targeting different regions of the viral spike. Thus, they say, the battle against coronavirus disease 2019 (COVID-19) could be opened on separate fronts, much like the approach Ho and others have studied in HIV and some forms of cancer.

Selected abstracts in cardio-oncology, findings for AMG 510, and lurbinectedin as a second-line treatment in SCLC.

Four studies were highlighted that amplified the 3 components of using genetic testing in cancer treatment and prevention: (1) understanding the germline component of a tumor test, (2) broadening access to genetic counselors with video sessions, and (3) making sure risk assessment of each patient is accurate, so that patients do not have unnecessary surgeries.

Featuring findings from the KEYNOTE-177, ARAURA, ASPEN, and CITYSCAPE trials, and new results from MURANO.